biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
IO Biotech projects
9 ClinicalTrials.gov programs sponsored by IO Biotech.
IO Biotech has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IO102
IO Biotech
NSCLC
1 trial -
IO102-IO103
IO Biotech
Melanoma
2 trials -
IO102-IO103 in combination with pembrolizumab
IO Biotech
Lung Cancer Non Small Cell
1 trial -
IOB-022/KN-D38
IO Biotech
Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial -
IRX4204
IO Biotech
Psoriasis
1 trial -
NRX 194204
IO Biotech
Castration Resistant Prostate Cancer
1 trial -
PD-L1 peptide
IO Biotech
Smoldering Multiple Myeloma
1 trial -
PD-L1, PD-L2 peptides with Montanide ISA51
IO Biotech
Chronic Lymphocytic Leukemia
1 trial -
Pembrolizumab
IO Biotech
Head and Neck Squamous Cell Carcinoma
1 trial
Frequently asked questions
How many clinical projects does IO Biotech have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.